Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Okines, A ^a   Verheij, M ^b   Allum, W ^c   Cunningham, D ^a   Cervantes, A ^d  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; TRASTUZUMAB;

ADVANCED CANCER; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; GASTRECTOMY; GASTROSCOPY; GERIATRIC PATIENT; HUMAN; LAPAROSCOPIC SURGERY; LYMPHADENECTOMY; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; STOMACH BIOPSY; STOMACH CANCER; SURGICAL TECHNIQUE; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; EUROPE; FOLLOW-UP STUDIES; GASTROSCOPY; HUMANS; INCIDENCE; META-ANALYSIS AS TOPIC; NEOPLASM METASTASIS; NEOPLASM STAGING; PALLIATIVE CARE; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77954322183     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq164     Document Type: Article

References (37)

1. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592.
2. Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 2006; 20: 633-649.
3. Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 872-878.
4. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354-362.
5. Sobin LW. TNM Classification of Malignant Tumours, 6th Edition (UICC). 2002.
6. The American Joint Committee on Cancer's Cancer Staging Handbook. Springer 2009.
7. Sano T, Kobori O, Muto T. Lymph node metastasis from early gastric cancer: endoscopic resection of tumour. Br J Surg 1992; 79: 241-244.
8. Wu CW, Hsiung CA, Lo SS et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006; 7: 309-315.
9. Sasako M, Sano T, Yamamoto S et al. D2 lymphadenectomy alone or with paraaortic nodal dissection for gastric cancer. N Engl J Med 2008; 359: 453-462.
10. Bonenkamp JJ, Hermans J, Sasako M et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340: 908-914.
11. Cuschieri A, Fayers P, Fielding J et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial.The Surgical Cooperative Group. Lancet 1996; 347: 995-999.
12. Songun IPH, Meershoek-Klein Kranenbarg E, van de Velde CJH. on behalf of the DGCG. 15-years follow-up results of the randomized Dutch D1D2 trial: lower cancer-related morbidity after D2. ECCO 15-ESMO34, Berlin. Eur J Cancer 2009; 20 (Suppl): 46LBA.
13. In International Gastric Cancer Association Consensus meeting 2009. Krakow: Poland 2009.
14. Memon MA, Khan S, Yunus RM et al. Meta-analysis of laparoscopic and open distal gastrectomy for gastric carcinoma. Surg Endosc 2008; 22: 1781-1789.
15. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
16. Boige V, Pignon J, Saint-Aubert B et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07- FFCD 9703 trial (Meeting Abstracts). J Clin Oncol 2007; 25: 4510.
17. MacDonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
18. Kim S, Lim DH, Lee J et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005; 63: 1279-1285.
19. Jansen EP, Boot H, Verheij M, van de Velde CJ. Optimal locoregional treatment in gastric cancer. J Clin Oncol 2005; 23: 4509-4517.
20. Liu TS, Wang Y, Chen SY, Sun YH. An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. Eur J Surg Oncol 2008; 34: 1208-1216.
21. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.
22. Ajani JA, Winter K, Okawara GS et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 2006; 24: 3953-3958.
23. Stahl M, Walz MK, Stuschke M et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851-856.
24. Wagner AD, Unverzagt S, Grothe W, Kleber J, Grothey A, Haerting J et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; 3: CD004064.
25. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as firstline therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997.
26. Tebbutt N, Strickland A, Van Hazel G et al. ATTAX: randomised phase II study evaluating weekly docetaxel-based chemotherapy combinations in advanced esophago-gastric cancer, final results of an AGITG trial In ASCO 2007. ASCO Annual Meeting Proceedings. J Clin Oncol 2007: 4528.
27. Dank M, Zaluski J, Barone C et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19: 1450-1457.
28. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
29. Starling N, Rao S, Cunningham D et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009; 27: 3786-3793.
30. Kang YK, Kang WK, Shin DB et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009; 20: 666-673.
31. Al-Batran SE, Hartmann JT, Probst S et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26: 1435-1442.
32. Okines AF, Norman AR, McCloud P et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009; 20: 1529-1534.
33. Van Cutsem E, Chung H, Shen L. Efficacy results from the ToGA trial: A phase III stduy of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) In ASCO Annual Meeting, Orlando, FL, USA. J Clin Oncol 2009; LBA4509.
34. Thuss-Patience PC, Deist T, Hinke A. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) In ASCO Annual Meeting, Orlando, FL, USA. J Clin Oncol 2009; Abstr 4540.
35. Tey J, Back MF, Shakespeare TP et al. The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int J Radiat Oncol Biol Phys 2007; 67: 385-388.
36. Trumper M, Ross PJ, Cunningham D et al. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. Eur J Cancer 2006; 42: 827-834.
37. Lacueva FJ, Calpena R, Medrano J et al. Follow-up of patients resected for gastric cancer. J Surg Oncol 1995; 60: 174-179.